Description(s):
EGFR (Epidermal Growth Factor Receptor) is a transmembrane tyrosine kinase receptor that plays a crucial role in cell growth, division, and death. Mutations in the EGFR gene can lead to abnormal activation of the receptor, contributing to the development and progression of certain cancers.
 
Signosis has developed EL-040, a Ba/F3 cell line expressing EGFR that includes point mutations that changes a L (Leu) into an Q (Gln) at point 718, a L into an R (Arg) at point 858, and a T (Thr) into an M (Met) at point 790. The C797S mutation in particular is known to confer resistance to third gen EGFR tyrosine kinase inhibitors (TKIs) such as osimertinib and poziotinib, while the T790M is known to confer secondary resistance to first gen EGFR TKIs.
 
This cell line was established by electroporation to transfect Ba/F3 cells a vector containing the mutated EGFR gene with GFP and hygromycin resistance. Clones with resistance to hygroymcin were subsequently screened for GFP expression, with protein expression of the mutant EGFR tested via western blot. The clone with the highest expression were selected and expanded to produce this stable cell line.